Regenxbio Inc(RGNX) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 29 at 5:25 PM ET (Korea 10/30 06:25)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -3.79 | Insider Own | 7.51% | Shs Outstand | 66.0M | Perf Week | 3.56% |
| Market Cap | 0.49B | Forward P/E | - | EPS next Y | 13.81% | Insider Trans | 0.58% | Shs Float | 61.1M | Perf Month | -1.39% |
| Enterprise Value | 0.63B | PEG | - | EPS next Q | -1.24 | Inst Own | 63.71% | Short Float | 16.45% | Perf Quarter | -23.37% |
| Income | -0.20B | P/S | 2.81 | EPS this Y | 11.18% | Inst Trans | 1.79% | Short Ratio | 7.4 | Perf Half Y | -17.22% |
| Sales | 0.17B | P/B | 5.6 | EPS next 5Y | 26.67% | ROA | -40.6% | Short Interest | 10.04M | Perf YTD | -48.44% |
| Book/sh | 1.32 | P/C | 4.64 | EPS past 3/5Y | 16.67% -4.73% | ROE | -137.63% | 52W High | -54.14% ($16.19) | Perf Year | -42.17% |
| Cash/sh | 1.6 | P/FCF | - | Sales past 3/5Y | 14.78% 1.97% | ROIC | -68.18% | 52W Low | 36.11% ($5.45) | Perf 3Y | -48.37% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -9.21% | Gross Margin | 77.57% | Volatility(W/M) | 6.95% 6.6% | Perf 5Y | -79.05% |
| Dividend TTM | - | EV/Sales | 3.64 | Sales Y/Y TTM | 12% | Oper. Margin | -94.08% | ATR (14) | 0.49 | Perf 10Y | -53.3% |
| Dividend Ex-Date | - | Quick Ratio | 2.86 | EPS Q/Q | 131.11% | Profit Margin | -112.58% | RSI (14) | 49.54 | Recom | 1.5 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.86 | Sales Q/Q | 405.73% | SMA20 | 1.85% ($7.3) | Beta | 1.24 | Target Price | $21.83 |
| Payout | - | Debt/Eq | 3.49 | Earnings | 2026/8/6 | SMA50 | -7.88% ($8.07) | Rel Volume | 0.76 | Prev Close | $7.24 |
| Employees | 371 | LT Debt/Eq | 3.01 | EPS/Sales Surpr. | 446.38% 10.64% | SMA200 | -19.38% ($9.22) | Avg Volume(3M) | 1.36M | Price | $7.43 |
| IPO | 2015/9/17 | Option/Short | Yes/Yes | Trades | 6797 | Volume | 1,033,053 | Change | 2.56% |
🧬 Regenxbio (ticker RGNX) is a US biotech company developing gene therapies based on adeno-associated virus (AAV) vectors. Through its proprietary NAV technology platform, it has built a diverse portfolio of AAV vectors and maintains a gene therapy pipeline targeting Duchenne muscular dystrophy, rare genetic diseases, and ophthalmologic conditions.
Over the past 1 year, on the lower side
54% below its 1-year high.
Traded less than usual. That is 76% of its average volume.
RGNX has a sound balance sheet but weak earning power
Of every $100 in sales, $94.08 is lost.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +11.2% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $281. Peers typically go for $1,237. It is about in line with its own 1-year average.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -79.0%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Ownership is about average
Institutions hold 63.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #223 of 594 in the industry
Based on market cap of $490M.
FAQ
What kind of company is RGNX?
RGNX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of RGNX?
The market cap of RGNX is approximately $490M, ranking 3,183 within its sector.
What is the 52-week high and low for RGNX?
RGNX has recorded a 52-week high of $16.19 and a low of $5.45.
